Favorable outcome in infants with AML after intensive first- and second-line treatment: An AML-BFM study group report

Leukemia

Volumn 26, Issue 4, 2012, Pages 654-661

  Creutzig, U ^a,b   Zimmermann, M ^b   Bourquin, J P ^c   Dworzak, M N ^d   Kremens, B ^e   Lehrnbecher, T ^f   Von Neuhoff, C ^b   Sander, A ^b   Von Stackelberg, A ^g   Schmid, I ^h   Stary J ^i,j   Steinbach, D ^k   Vormoor, J ^l   Reinhardt, D ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Czech Pediatric Hematology Working Group (CPH)   (Czech Republic)

^k UNIVERSITY HOSPITAL ULM   (Germany)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

acute myeloid leukemia; children; infants; treatment

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INFANT; INFANT MORTALITY; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84859646588     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.267     Document Type: Article

References (36)

1. Sorensen PH, Chen CS, Smith FO, Arthur DC, Domer PH, Bernstein ID et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994; 93: 429-437. (Pubitemid 24030865)
2. Pui CH, Raimondi SC, Srivastava DK, Tong X, Behm FG, Razzouk B et al. Prognostic factors in infants with acute myeloid leukemia. Leukemia 2000; 14: 684-687. (Pubitemid 30195460)
3. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639-649. (Pubitemid 37328819)
4. Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105: 3749-3756. (Pubitemid 40628227)
5. Pieters R. Infant acute lymphoblastic leukemia: lessons learned and future directions. Curr Hematol Malig Rep 2009; 4: 167-174.
6. Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the japan infant leukemia study group. Blood 2001; 98: 3589-3594.
7. Webb DK, Harrison G, Stevens R, Gibson BG, Hann I, Wheatley K. Relationship between age at diagnosis, clinical features, and outcome of therapy in children treated in the medical research concil AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714-1720.
8. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in pediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042. (Pubitemid 41741595)
9. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682-2689.
10. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499-4506. (Pubitemid 46646248)
11. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr. Blood Cancer 2011; 57: 986-992.
12. Periclou AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996; 39: 42-50. (Pubitemid 26400659)
13. Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U. Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children. Klin Padiatr 2002; 214: 188-194. (Pubitemid 34925495)
14. Kaspers GJL, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O et al. Addition of liposomal daunorubicin (DaunoXomes) to FLAG significantly improves treatment response in pediatric relapsed AML: final results from the international randomised phase III study relapsed AML 2001/01 [abstract]. Blood 2009; 114: 13-14.
15. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428.
16. Groll AH, Ritter J, Muller FM. Prevention of fungal infections in children and adolescents with cancer. Klin Padiatr 2001; 213 (Suppl 1): A50-A68. (Pubitemid 32881864)
17. Simon A, Fleischhack G, Marklein G, Ritter J. Antimicrobial prophylaxis of bacterial infections in pediatric oncology patients. Klin Padiatr 2001; 213(Suppl 1): A22-A37. (Pubitemid 32881862)
18. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al. Report of the national cancer institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819. (Pubitemid 20148273)
19. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. Wiley: New York, NY, 2002.
20. Vormoor J, Ritter J, Creutzig U, Boos J, Heyen P, Ludwig W-D et al. Acute myelogenous leukaemia in children under 2 years - experiences of the west german AML studies BFM-78, -83 and -87. Br J Cancer 1992; 66(Suppl XVIII): 63-67.
21. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114: 2489-2496.
22. Testi AM, Biondi A, Lo CF, Moleti ML, Giona F, Vignetti M et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453. (Pubitemid 40981236)
23. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 2010; 149: 399-409.
24. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
25. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257-268. (Pubitemid 351722945)
26. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630-639. (Pubitemid 29119294)
27. Holm-Knudson RJ, Rasmussen LS. Paediatric airway management: basic aspects. Acta Anaesthesiol Scand 2009; 53: 1-9.
28. Baker KS, Bresters D, Sande JE. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. Pediatr Clin North Am 2010; 57: 323-342.
29. Ishii E, Kawasaki H, Isoyama K, Eguchi-Ishimae M, Eguchi M. Recent advances in the treatment of infant acute myeloid leukemia. Leuk Lymphoma 2003; 44: 741-748. (Pubitemid 36410977)
30. Reinhardt D, Thiele C, Creutzig U. Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation. Klin Pädiatr 2002; 214: 22-29. (Pubitemid 34084389)
31. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10: 293-310. (Pubitemid 39492075)
32. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
33. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
34. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250. (Pubitemid 47082422)
35. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62. (Pubitemid 32061242)
36. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122: 217-225. (Pubitemid 36859606)